Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IQWiG rebuffs Pfizer's Xalkori

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) said in a preliminary benefit assessment that Xalkori crizotinib

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE